Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/169503
Full metadata record
DC FieldValueLanguage
dc.creatorAzevedo, CM-
dc.creatorXie, B-
dc.creatorGunn, WG-
dc.creatorPeralta, RM-
dc.creatorDantas, CS-
dc.creatorFernandes-Mendes, H-
dc.creatorJoshi, S-
dc.creatorDean, V-
dc.creatorAlmeida, P-
dc.creatorWilfahrt, D-
dc.creatorMendes, N-
dc.creatorPortero, JL-
dc.creatorC, Poves-
dc.creatorFernández-Aceñero, MJ-
dc.creatorMarcos-Pinto, R-
dc.creatorFernandes, Â-
dc.creatorDelgoffe, GM-
dc.creatorPinho, SS-
dc.date.accessioned2025-10-03T17:23:57Z-
dc.date.available2025-10-03T17:23:57Z-
dc.date.issued2025-
dc.identifier.issn2326-6066-
dc.identifier.urihttps://hdl.handle.net/10216/169503-
dc.description.abstractT-cell therapies have transformed cancer treatment. While surface glycans have been shown to play critical roles in regulating T-cell development and function, whether and how the glycome influences T cell–mediated tumor immunity remains an area of active investigation. In this study, we show that the intratumoral T-cell glycome is altered early in human colorectal cancer, with substantial changes in branched N-glycans. We demonstrated that CD8+ T cells expressing β1,6-GlcNAc branched N-glycans adopted an exhausted phenotype, marked by increased PD1 and Tim3 expression. CRISPR/Cas9 deletion of key branching glycosyltransferase genes revealed that Mgat5 played a prominent role in T-cell exhaustion. In culture-based assays and tumor studies, Mgat5 deletion in CD8+ T cells resulted in improved cancer cell killing. These findings prompted assessment of whether MGAT5 deletion in anti-CD19 chimeric-antigen receptor (CAR) T cells could enable this therapeutic modality in a solid tumor setting. We showed that MGAT5 KO anti-CD19-CAR T cells inhibited the growth of CD19-transduced tumors. Together, these findings show that MGAT5-mediated branched N-glycans regulate CD8+ T-cell function in cancer and provide a strategy to enhance antitumor activity of native and CAR T cells.pt_PT
dc.description.sponsorshipS.S.P acknowledges Mizutani Foundation for Glycoscience (Grant 250007) for funding. SSP also acknowledges Liga Portuguesa Contra o Cancro LPCC/MULTICARE for funding (C 3035006C17); Portuguese Society of Digestive Endoscopy (SPED) and Porto Comprehensive Cancer Center Raquel Seruca (P.CCC Raquel Seruca) for the support. S.S.P acknowledges the Portuguese Foundation for Science and Technology (FCT - 2023.16654.ICDT) for funding. Co-funded by the European Union (ERC, GlycanSwitch, 101071386). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. GMD acknowledges the National Institutes of Health (NIH) [R01AI171483, R01AI166598, R01CA277473], the Alliance for Cancer Gene Therapy, the Mark Foundation for Cancer Research’s Emerging Leader Award, a Cancer Research Institute’s Lloyd J. Old STAR Award, and the Sy Holzer Endowed Immunotherapy Fund. ÂF acknowledges the Portuguese Foundation for Science and Technology (FCT) (2022.01422. PTDC) and Sociedade Portuguesa de Neurologia (SPN – Grant Pereira Monteiro) for funding. CMA acknowledges FCT [BD/07357/2021], Fulbright and FLAD for PhD fellowship and funding. We also thank Professor Ronald A. DePinho, University of Texas MD Anderson Cancer Center for his critical scientific inputs in revising this manuscript.pt_PT
dc.language.isoengpt_PT
dc.publisherAmerican Association for Cancer Researchpt_PT
dc.relationinfo:eu-repo/grantAgreement/EC/HE/101071386/EU-
dc.relationinfo:eu-repo/grantAgreement/FCT/Concurso de Projetos de I&D em Todos os Domínios Científicos - 2022/2022.01422.PTDC/PT-
dc.relation.ispartofseriesCancer immunology research, vol. 13(10), p. 1655-1673pt_PT
dc.rightsopenAccesspt_PT
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.meshAnimals-
dc.subject.meshCD8-Positive T-Lymphocytes/ immunology-
dc.subject.meshCD8-Positive T-Lymphocytes/ metabolism-
dc.subject.meshCell Line, Tumor-
dc.subject.meshColorectal Neoplasms/ immunology-
dc.subject.meshColorectal Neoplasms/ metabolism-
dc.subject.meshColorectal Neoplasms/ pathology-
dc.subject.meshColorectal Neoplasms/ therapy-
dc.subject.meshCytotoxicity, Immunologic-
dc.subject.meshGlycosylation-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy, Adoptive / methods-
dc.subject.meshMice-
dc.subject.meshN-Acetylglucosaminyltransferases / genetics-
dc.subject.meshN-Acetylglucosaminyltransferases / metabolism-
dc.subject.meshPolysaccharides / metabolism-
dc.titleReprogramming CD8+ T-cell Branched N-Glycosylation Limits Exhaustion, Enhancing Cytotoxicity and Tumor Killinpt_PT
dc.typeArtigo em Revista Científica Internacionalpt_PT
dc.contributor.uportoInstituto de Investigação e Inovação em Saúdept_PT
dc.identifier.doi10.1158/2326-6066.CIR-25-0313-
dc.relation.publisherversionhttps://aacrjournals.org/cancerimmunolres/article-abstract/13/10/1655/765468/Reprogramming-CD8-T-cell-Branched-N-Glycosylation?redirectedFrom=fulltext-
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
CIR_Azevedo et al AAM.pdf2.19 MBAdobe PDFThumbnail
View/Open
CIR_Azevedo et al Suplementary data.pdf1.06 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons